First product shipped from Sharps' facility in Hungary and first to support the Nephron Pharmaceuticals distribution and sales collaboration Sharps anticipates 1.3 million units to be commercially available in February 2023 with additional shipments to follow and new products to be added ...

High-Value specialized prefillable syringe systems to accelerate revenue growth in 2023 and beyond Company to launch next generation specialty polymer-based syringe products for the healthcare market NEW YORK, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “...

Company now transitions from a pre-revenue research & development start-up to a revenue generating manufacturing company Shipments to commence by the end of the year to support the recently announced distribution and sales agreement with Nephron Pharmaceuticals and its European cust...

Company anticipates products to be available in the first quarter of 2023 with initial revenue from this agreement expected in the first half of the year Strengthens the collaboration between Sharps and Nephron to advance the previously announced Inject-EZ startup in South Carolina in e...

WEST COLUMBIA, S.C. and NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Nephron Pharmaceuticals Corporation and Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery company offering patente...